ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In recent years, the prognosis of CML patients has been improved due to the promotion of tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib, nilotinib (NIL) and ponatinib, inhibiting the kinase activity of BCR-ABL1 by targeting its adenosine triphosphate (ATP) -binding site (Jabbour and Kantarjian, 2016).